1147557-97-8

Basic information

• Product Name: tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate
• Synonyms: tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate;6-oxo-2-azaspiro[3.3]heptane-2-carboxylate;2-Boc-6-hydroxy-2-aza-spi...;2-Boc-6-hydroxy-2-aza-spiro[3.3]heptane;6-Hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester;2-Azaspiro[3.3]heptane-2-carboxylic acid, 6-hydroxy-, 1,1-diMethylethyl ester;6-Hydroxy-2-azaspiro[3.3]heptane, N-BOC protected;tert-Butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate, 2-(tert-Butoxycarbonyl)-6-hydroxy-2-azaspiro[3.3]heptane
• CAS NO: 1147557-97-8
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27346
• Mol File: 1147557-97-8.mol

Chemical Properties

• Melting Point: 127-129℃
• Boiling Point: 316.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.17
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 14.84±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate(1147557-97-8)
• EPA Substance Registry System: tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate(1147557-97-8)

Safety Data

• Hazardous Substances Data: 1147557-97-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate is used as a key reactant for the synthesis of pharmaceuticals, particularly for the development of CNS penetrant CXCR2 antagonists. These antagonists have the potential to treat CNS demyelinating conditions, which are characterized by the loss of the protective myelin sheath surrounding nerve fibers in the central nervous system.
Used in the Treatment of CNS Demyelinating Conditions:
In the pharmaceutical industry, tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate is used as a building block for the creation of novel therapeutic agents that target CXCR2 receptors. By modulating the activity of these receptors, the synthesized compounds can potentially alleviate the symptoms and progression of CNS demyelinating conditions, such as multiple sclerosis.
Used in Drug Development Research:
In addition to its direct application in pharmaceutical synthesis, tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate also serves as a valuable research tool in drug development. Its unique chemical properties and structural features make it an attractive candidate for further exploration and optimization, potentially leading to the discovery of new and more effective treatments for a range of medical conditions.

Upstream product

• 1181816-16-9 tert-butyl 6-(benzyloxy)-2-azaspiro[3.3]heptane-2-carboxylate 
• 1239320-10-5 5,5-dichloro-6-oxo-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester 
• 1181816-12-5 6-oxo-2-aza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester 
• 934664-41-2 3-methylene-azetidine-1-carboxylic acid tert-butyl ester 
• 1314984-00-3 3-methylazetidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1181816-12-5 6-oxo-2-aza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester 
• 1421270-71-4 (±)-tert-butyl 6-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate 
• 1421270-66-7 C₂₂H₂₂Cl₂FN₅O*CH₂O₂ 
• 1448850-34-7 tert-butyl 6-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate 
• 1211526-53-2 2-[(tert-butoxy)carbonyl]-2-azaspiro[3.3]heptane-6-carboxylic acid 

Relevant articles and documents

AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS

Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.

Stereoselective Diboration of Spirocyclobutenes: A Platform for the Synthesis of Spirocycles with Orthogonal Exit Vectors

The diastereo- and enantioselective diboration of spirocyclobutenes provides a platform for the rapid preparation of a wide variety of chiral spirocyclic building blocks. The chemoselective functionalization of the carbon-boron bond in the products, including a stereospecific sp3-sp2 Suzuki–Miyaura cross-coupling reaction, provides a powerful tool to control the directionality and the nature of the exit vectors in the spirocyclic framework.

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

TARGETING COMPOUNDS

The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR

This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X1; X2; X3; X4; R1 R2 and R4 are as defined herein.

FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

B-LACTAMASE INHIBITOR AND APPLICATION THEREOF

The present invention relates to a compound of Formula (I)-(IV) useful as β-lactamase inhibitor, a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, wherein R1, R2, M and ring A have definitions as those in the specification. The present invention further relates to methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and uses of these compounds. For example, the compounds of the present invention can be used as β-lactamase inhibitors, for treatment and/or prophylaxis of diseases caused by bacterial infections, solving drug-resistance problems caused by β-lactamases, especially bacterial drug-resistant diseases caused by type B metallo-β-lactamases.

THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE

The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.

Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions

Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.

1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors with a Novel Monodentate Binding Interaction

Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.